SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Rat dog micro-cap picks--now moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ~digs who wrote (54)2/18/2004 12:16:12 PM
From: Bucky Katt   of 1338
 
GENE hit a new high on FDA news,, Genome Therapeutics Corp.'s (GENE) clinical candidate, Ramoplanin, has received fast-track status from the Food and Drug Administration for the treatment of Clostridium difficile-associated diarrhea.

In a press release, the company said Ramoplanin is in Phase II development for this indication. It said this program is nearing completion, and the company expects to announce preliminary data from the trial in the coming months. Subsequently, subject to the completion and review of the Phase II trial, the Phase III program for Ramoplanin for the treatment of C. difficile-associated diarrhea is slated to begin later this year.

Genome Therapeutics is a biopharmaceutical company committed to the development and commercialization of novel anti-infective therapeutics.

Company Web Site: genomecorp.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News